

Date: May 20, 2026

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai- 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub.: Submission of Media Release

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Audited Standalone and Consolidated financial results of the Company for the half year and financial year ended March 31, 2026 duly approved by the Board of Directors of the Company in their meeting held on May 20, 2026.

You are requested to take the same on your record.

Thanking You.

For, Remus Pharmaceuticals Limited

Deval Patel

Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl.: As above

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

REMUS PHARMACEUTICALS LIMITED ANNOUNCES FINANCIAL RESULTS FOR THE SECOND HALF AND FINANCIAL YEAR ENDED MARCH 31, 2026

May 20, 2026: Remus Pharmaceuticals Limited (NSE-SME: REMUS) announces its results for the second half and financial year ended March 31, 2026


Consolidated Financial Performance:

FY26 vs FY25


Revenue From Operations

 FY26: ₹ 853.63 Cr
FY25: ₹ 620.36 Cr
YoY Growth: 37.60%

EBITDA


 FY26: ₹ 56.69 Cr
FY25: ₹ 45.69 Cr
YoY Growth: 24.08%

PAT


 FY26: ₹ 46.17 Cr
FY25: ₹ 38.42 Cr
YoY Growth: 20.18%

H2 FY26 vs H1 FY26


Revenue From Operations

 H2 FY26: ₹ 453.43 Cr
H1 FY26: ₹ 400.20 Cr
Growth: 13.30%

EBITDA


 H2 FY26: ₹ 29.78 Cr
H1 FY26: ₹ 26.91 Cr
Growth: 10.68%

PAT


 H2 FY26: ₹ 24.58 Cr
H1 FY26: ₹ 21.59 Cr
Growth: 13.86%

H2 FY26 vs H2 FY25


Revenue From Operations

 H2 FY26: ₹ 453.43 Cr
H2 FY25: ₹ 347.75 Cr
Growth: 30.39%

EBITDA

 H2 FY26: ₹ 29.78 Cr
H2 FY25: ₹ 24.52 Cr
Growth: 21.45%

PAT

 H2 FY26: ₹ 24.58 Cr
H2 FY25: ₹ 20.57 Cr
Growth: 19.51%

H2-FY26 Business Highlights:

- In-licensed **Rifaximin** (200 mg & 550 mg) and **Fexofenadine** 180 mg for key markets including **Mexico, Chile, Vietnam, and Peru**, supported by bioequivalence (BE) studies, strengthening the anti-infective and anti-allergy portfolio.
- Secured a direct government tender in **Nicaragua** for **Ceftazidime + Avibactam 2.5 g Injection**, while also progressing regulatory filings in multiple international markets.
- Initiated filings for **Semaglutide tablets and injections** across non-patented emerging markets through both B2B and B2C channels, marking entry into the fast-growing GLP-1 and anti-obesity segment.
- Executed supply orders for **Rivastigmine Patch** in **Venezuela** and initiated filings in Venezuela and other markets, expanding the CNS portfolio.

- **In-licensed Peg-filgrastim and Filgrastim** PFS injections for the **Philippines and Vietnam** markets, with regulatory submissions planned in the coming months, strengthening the oncology pipeline.
- Awarded the **NUPCO tender** for **Topiramate capsules** in February 2026, with registrations underway, further strengthening the institutional business in **Saudi Arabia**.
- Secured a tender in **North Macedonia** for **Anti-TB** combinations, including Rifampicin + Isoniazid and four-drug fixed-dose combinations, with supplies planned from an **EU-GMP** approved manufacturing site.
- Expanded the **Urology** portfolio with the **launch** of **Mirabegron 25 mg XR** in Venezuela, Ecuador, and Bolivia, along with **Mirabegron + Solifenacin** in Ecuador.
- Successfully **cleared** the **Peru DIGEMID audit** in **February 2026**, strengthening the company's regulatory credibility and further expansion across Peru and broader Latin American markets. Planning on filling **50+ new registration** in next 4 months.
- Filed **five products** to **ISP Chile** and in-licensed **Dapagliflozin 10 mg tablets** and **Rivaroxaban 3 SKUs** with Bioequivalence studies for the Chile market.
- Through **geographic expansion** strategy Remus Expanded its commercial presence into four new markets – **Myanmar, Nicaragua, North Macedonia, and Madagascar**.
- Under **Relius** in **Bolivia, launched 26** products through the **B2C segment**, with 40 additional launches planned over the next six months.
- **Registered** niche specialty product **Triptorelin Injection 11.25 mg in Bolivia**, it will be strengthening the **specialty** injection portfolio.
- **Launched** the **CNS portfolio** in **Relius Bolivia** through D2C channels with products including Brivaracetam, Valproic Acid, Risperidone, and Lamotrigine tablets.
- Finalized a **multi-country agreement** with **MNC** and submitted Ondansetron Injection dossiers across **five African markets**.

Management Comments:

Commenting on the results, Mr. Arpit Deepakkumar Shah, Managing Director of Remus Pharmaceuticals Limited said, *"I am incredibly proud to report that we have delivered an exceptional financial performance for the FY 2026. This is a direct reflection of our team's resilience, operational discipline, and unwavering focus on delivering value to our customers.*

What makes these results particularly satisfying is that they were achieved against a backdrop of complex macroeconomic conditions. By proactively managing our supply chains and optimizing our cost structures. This financial agility allowed us to not only protect our bottom line but to reinvest heavily into our core business.

A major driver of this year's success was the strong growth of our B2C entity Relius which exceeded our own internal projections. This validates our strategic decision to pivot toward our Strategic Focus of entering directly in pharmacies to take advantage of higher-margin products.

As we look ahead to FY 2027, we are armed with the liquidity and the strategic clarity to accelerate our expansion plans. We will continue to aggressively pursue disciplined, profitable growth, ensuring we generate sustainable, long-term value for our shareholders, our employees, and the communities in which we operate."

Financial Statements:

Results for the second half and financial year ended March 31, 2026, prepared under Ind AS, are available in the Investors section of our website <https://remuspharma.com/>

About Remus Pharmaceuticals Limited:

Remus Pharmaceuticals Limited (NSE-SME: REMUS) is engaged in exporting, marketing and distribution of finished formulations of pharmaceutical drugs as well as API (Active Pharmaceutical Ingredient). Having strong footprints in 40+ countries across the globe, Remus is involved in the sales of niche, specialized and critical care finished formulations. Along with it they are providing technical consultancy services to various distributors for preparation of reports on the dossiers of the products, to be registered by the said distributors in several countries.

Safe Harbor

This document includes certain forward-looking statements based on the current expectations and assumptions of the management of Remus Pharmaceuticals Limited and its subsidiaries ("Remus"). These statements are subject to various risks, uncertainties, and changes in economic, business, regulatory, technological, and market conditions, including exchange rate fluctuations and financing costs, which may cause actual results to differ materially from those expressed or implied. Remus, its directors, affiliates, and employees undertake no obligation to update, revise, or modify any forward-looking statements, whether as a result of new information, future events, or otherwise.

Follow Remus Pharmaceuticals Limited on LinkedIn: <https://www.linkedin.com/company/remus-pharmaceuticals/>

Contact Information:

<p>Investor Relations Representative: Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903-9500 Email: remus@valoremadvisors.com</p>	<p>Chief Financial Officer Ms. Anjali Shah Remus Pharmaceuticals Limited Email: ir@remuspharma.com</p>
---	---